BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions. Treatment of chronic total occlusions is one of the few remaining challenges in interventional cardiology today. Approximately 30% of all patients undergoing angiography present with a chronic total occlusion, resulting in a significant referral rate to more invasive bypass surgery. BridgePoint Medical's CrossBoss™ CTO Catheter and their Stingray™ CTO Re-Entry System are currently under investigation and may improve physician access to chronic total occlusions. The technologies utilize known interventional techniques and do not require cumbersome and expensive capital equipment.